Iterum Therapeutics
ITRM
ITRM was delisted on the 31st of March, 2026.
25 hedge funds and large institutions have $575K invested in Iterum Therapeutics in 2022 Q3 according to their latest regulatory filings, with 3 funds opening new positions, 7 increasing their positions, 8 reducing their positions, and 16 closing their positions.
2.39% more ownership
Funds ownership: 0.21% → 2.6% (+2.4%)
13% less repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 8
34% less funds holding
Funds holding: 38 → 25 (-13)
54% less capital invested
Capital invested by funds: $1.25M → $575K (-$672K)
81% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 16
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Dimensional Fund Advisors
Austin,
Texas
|
+$189K |
| 2 |
Jane Street
New York
|
+$85K |
| 3 |
Renaissance Technologies
New York
|
+$39.8K |
| 4 |
UBS Group
Zurich,
Switzerland
|
+$25.3K |
| 5 |
KF
Krilogy Financial
St. Louis,
Missouri
|
+$20.2K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CPX
Canaan Partners X
Menlo Park,
California
|
-$351K |
| 2 |
Goldman Sachs
New York
|
-$61K |
| 3 |
GCP
GSA Capital Partners
London,
United Kingdom
|
-$61K |
| 4 |
Verition Fund Management
Greenwich,
Connecticut
|
-$23K |
| 5 |
VF
Virtu Financial
New York
|
-$22K |
ITRM Hedge Fund Activity: Q3 2022 in Review
25 institutional investors reported a position in Iterum Therapeutics (ITRM) for Q3 2022, worth a combined $575K — down 54% from $1.25M a quarter earlier.
Sellers outnumbered buyers: 16 funds closed out of ITRM and 3 opened new positions — a net loss of 13 holders — while 8 trimmed existing stakes and 7 added.
The largest buyer was Dimensional Fund Advisors, opening a new position worth an estimated $189K. The largest seller was Canaan Partners X, exiting entirely with an estimated $351K sold.
- 25 institutional investors held Iterum Therapeutics (ITRM) as of Q3 2022, down from 38 in Q2 2022.
- Funds reported $575K of Iterum Therapeutics stock for Q3 2022, down 54% quarter-over-quarter.
- 3 funds opened new Iterum Therapeutics positions in Q3 2022 and 16 closed out, a net change of -13 holders.
- The largest Iterum Therapeutics buyer in Q3 2022 was Dimensional Fund Advisors, an estimated $189K added.
- The largest Iterum Therapeutics seller in Q3 2022 was Canaan Partners X, an estimated $351K sold.
Based on aggregated 13F filings for Q3 2022.